Tsubota Laboratory Incorporated (4890.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenJPY 256.00

From 52W high−38.82%

Volume15000.00

Market capJPY 6.71B

P/E (TTM)—

P/S (TTM)17.2x

Div yield—

Key dataSep 18, 2026

Open

JPY 256.00

From 52W high

−38.82%

Volume

15000.00

Market cap

JPY 6.71B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−8.4x

P/E (TTM)

—

RSI (14)

44.9

MomentumView details →

1D Return

+1.56%

YTD Return

−22.35%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−8.4x

EV/Sales

15.5x

P/S (TTM)

17.2x

P/B (TTM)

9.1x

ProfitabilityView details →

Gross Margin

165.76%

Net Margin

−56.20%

EBITDA Margin

37.15%

ROE (TTM)

−36.11%

ROA (TTM)

−23.86%

Asset Turnover

0.40x

GrowthView details →

Revenue YoY

−45.00%

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+19.27%

EPS CAGR 3Y

+48.21%

EBITDA YoY

—

MomentumView details →

1D Return

+1.56%

YTD Return

−22.35%

1Y Return

−24.57%

RSI (14)

44.9

vs 50D SMA

−0.11%

vs 200D SMA

−9.39%

Capital & dividendView details →

Debt/Equity

0.07x

Current Ratio

3.17x

Quick Ratio

3.16x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

710.00M

Net Income (TTM)

−399.00M

Op. CF (TTM)

—

Next earningsNov 6, 2026 →

Latest newsMore news →

Tsubota Laboratory announced on September 7 that it concluded a joint research agreement with Phirst to develop eye drops using ultra-fine bubble (UFB) water.13d ago

Tsubota Lab signed a joint research agreement with Falstroma for the development of eye drops using ultra-fine bubble water.13d ago

Similar companies

CellSource Co.,Ltd.4880.T Solasia Pharma K.K.4597.T BrightPath Biotherapeutics Co.,Ltd.4594.T Chiome Bioscience Inc.4583.T J-Pharma Co.,Ltd.520A.T Nano Holdings,Inc.4571.T Find similar companies →

Latest newsMore news →

Tsubota Laboratory announced on September 7 that it concluded a joint research agreement with Phirst to develop eye drops using ultra-fine bubble (UFB) water.13d ago Tsubota Lab signed a joint research agreement with Falstroma for the development of eye drops using ultra-fine bubble water.13d ago Tsubota Laboratory announced that the Phase 2a trial of TLM-001, an ophthalmic drug for meibomian gland dysfunction licensed to Maruho, achieved Last Patient Out on June 25, 2026.39d ago